Advanced Scientifics and Chemic Laboratories Announce Joint Cooperation Agreement

Article

Advanced Scientifics and Chemic Laboratories enter a three-year joint cooperation agreement to collaborate on product development projects.

Advanced Scientifics (ASI) and Chemic Laboratories reported a three-year joint cooperation agreement that will allow the two companies to collaborate on several product development projects in the pharmaceutical and biopharmaceutical markets, particularly in the areas of leachable and extractable analytical data supporting single-use systems (SUS).

The cooperation model between the two companies will consist of ASI developing film products and SUS systems for pharmaceutical and biopharmaceutical customers, while Chemic uses analytics to provide extractable data assessing material compatibility with model bioprocessing solutions.

Source: Advanced Scientifics

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!
Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Antibodies.com Moves to Expanded UK Headquarters

Susan Haigney
August 4th 2025
Article

The biological reagents provider is moving to a 5000-square-foot site in Cambridge Technopark to accommodate the company’s growth.

Survey with blurred city abstract lights background | Image Credit: © Tierney - stock.adobe.com

Survey: Impacts of Tariffs & Trade Policy on the Bio/pharmaceutical Industry

Christopher Cole
August 4th 2025
Article

Help us get a better picture of how new tariffs and trade policy have impacted you and your organization.

Headquarters and branches / Building office network | Image Credit: © CurvaBezier - stock.adobe.com

PL BioScience Expands Cell Culture Manufacturing Capacity to Meet Global HPL Demand

Christopher Cole
August 4th 2025
Article

Germany-based biotech boosts animal-free supplement production, enabling greater scalability and supply security for next-gen cell therapies worldwide.

Resignation concept in a professional office setting | Image Credit: © Jane Kelly - stock.adobe.com

FDA Shake-Up: Vinay Prasad Exits Amid Tumult in Biologics Oversight

Christopher Cole
August 4th 2025
Article

Prasad’s short FDA tenure brought stricter review standards for gene and COVID vaccines, sparking biotech concern and political backlash.

OleksKao - stock.adobe.com

AstraZeneca’s Imfinzi Advances in Gastric Cancer With FDA Priority Review

Christopher Cole
August 4th 2025
Article

Imfinzi’s application is supported by Phase III trial data showing improved pathologic complete response in early-stage gastric cancer.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF

Susan Haigney
August 4th 2025
Article

The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.

© 2025 MJH Life Sciences

All rights reserved.